FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 264 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... September 10, 2024 Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen... July 29, 2022 FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma August 24, 2021 The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to... June 12, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Ivosidenib EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib How Does Ovarian Cancer Form? A New Study Points to MicroRNA Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...
